# AstraZeneca (France)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/astrazeneca-france/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 48.5 |
| Citations | 82,739 |
| City | Courbevoie |
| Country | FR |
| Description | AstraZeneca (France) is a research organisation in Courbevoie, FR. OpenAlex records 1,424 works and 82,739 citations for it. 612 researchers list it as their most recent affiliation. |
| Homepage | https://www.astrazeneca.fr/ |
| OpenAlex ID | https://openalex.org/I4210110908 |
| Region | Île-de-France |
| Researchers | 612 |
| ROR ID | https://ror.org/016qv5070 |
| Type | company |
| Works | 1,424 |

## University papers

- [The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment](https://scholariq.org/papers/the-premier-study-a-multicenter-randomized-double-blind-clinical-trial-of/)
- [The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design](https://scholariq.org/papers/the-remap-cap-randomized-embedded-multifactorial-adaptive-platform-for-community/)
- [Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy](https://scholariq.org/papers/outcome-after-pathologic-complete-eradication-of-cytologically-proven-breast/)
- [Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes](https://scholariq.org/papers/invasive-lobular-carcinoma-classic-type-response-to-primary-chemotherapy-and/)
- [Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/quality-of-life-in-patients-with-advanced-renal-cell-carcinoma-given-nivolumab/)

## University top topics

Showing 8 of 25.

- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Respiratory and Cough-Related Research](https://scholariq.org/topics/respiratory-and-cough-related-research/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.